# A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

> **NCT06164951** · PHASE3 · COMPLETED · sponsor: **QED Therapeutics, a BridgeBio company** · enrollment: 114 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** Infigratinib 0.25 mg/kg/day
- **DRUG:** Placebo Comparator 0.25 mg/kg/day

## Key facts

- **NCT ID:** NCT06164951
- **Lead sponsor:** QED Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-10
- **Primary completion:** 2025-12-18
- **Final completion:** 2025-12-18
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06164951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06164951, "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06164951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*